ALK is a tractable therapeutic target in neuroblastoma, very likely to be susceptible to equally small-molecule tyrosine kinase GPCR SIGNALING inhibitors and therapeutic antibodies---as has been proven for other receptor tyrosine NF-κB Signaling kinases in malignancies these as breast and lung cancer.
